

Hayashi K, Katano Y, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, <u>Yoshioka K</u> , Toyoda H, Kumada T, Goto H	Association of Interleukin 28B polymorphism and mutations in the NS5A of hepatitis C virus genotype 2 with interferon responsiveness.	J Gastroenterol Hepatol	30(1)	178-83	2015
Ichino N, Osakabe K, Sugimoto K, Suzuki K, Yamada H, Takai H, Sugiyama H, Yukitake J, Inoue T, Ohashi K, Hata H, Hamajima N, Nishikawa T, Hashimoto S, Kawabe N, <u>Yoshioka K</u>	The NAFLD Index: A Simple and Accurate Screening Tool for the Prediction of Non-Alcoholic Fatty Liver Disease	Rinsho Byori	63(1)	32-43	2015
T. Nishikawa, S. Hashimoto, N. Kawabe, M. Harata, Y. Nitta, M. Murao, T. Nakano, Y. Mizuno, H. Shimazaki, T. Kan, K. Nakaoka, Y. Takagawa, M. Ohki, N. Ichino, K. Osakabe, <u>K. Yoshioka</u> .	Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C	World J Gastroenterol.	20(5)	1289-1297	2014
Shakado S, Sakisaka S, Okanou T, Chayama K, Izumi N, Toyoda J, Tanaka E, Ido A, Takehara T, <u>Yoshioka K</u> , Hiasa Y, Nomura H, Seike M, Ueno Y, Kumada H	Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan.	Hepatol Res	44(9)	983-992	2014
川部直人、橋本千樹、原田雅生、新田佳史、村尾道人、中野卓二、嶋崎宏明、水野裕子、菅敏樹、中岡和徳、大城昌史、高川友花、福井愛子、 <u>吉岡健太郎</u>	C型肝炎治療困難例に対する瀉血療法、IFN-β療法、脾摘/PSE後のPeg-IFN療法の検討	消化器内科	58(3)	405-412	2014
<u>吉岡健太郎</u>	急性肝炎	臨床雑誌 内科6増大号	113(6)	1074-5	2014
<u>吉岡健太郎</u>	ChallengeQUIZ貴方も名医	CLINIC magazine	540(6)	37,68-9	2014

高川友花、川部直人、橋本千樹、原田雅生、村尾道人、新田佳史、中野卓二、嶋崎宏明、水野裕子、菅敏樹、中岡和徳、大城昌史、 <u>吉岡健太郎</u>	C型肝硬変に合併した多発肝MALTリンパ腫の1例	肝臓	55(5)	274-283	2014
Sato K, Goshō M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, Nakade Y, Ito K, Fukuzawa Y, <u>Yoneda M</u>	Vitamin E has a beneficial efficacy on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.	Nutrition (in press)			
<u>Yoneda M</u> , Hasegawa T, Sato K	Vitamin E therapy on NAFLD/NASH.	Nutrition (in press)			
Kobayashi K, Nakao H, Nishiyama T, Lin Y, Kikuchi S, Kobayashi Y, Yamamoto T, Ishii N, Ohashi T, Satoh K, Nakade Y, Ito K, <u>Yoneda M</u>	Diagnostic accuracy of real-time tissue elastography for the staging of liver fibrosis: a meta-analysis.	Eur Radiol	25(1)	230-8	2015
Ito K, Yotsuyanagi H, Yatsuhashi H, Krino Y, Takikawa Y, Saito t, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, <u>Yoneda M</u> , Mita E, Yamamoto K, Michitaka K, Meshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, Masaki N, Mizokami M; Japanese AHB Study Group.	Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults.	Hepatology	59(1)	89-97	2014
Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamura M, Izumi N, Watanabe S, Tsubota A, Komatsu M, Masaki T, Enomoto N, <u>Yoneda M</u> , Murata K, Ito K, Koike K, Mizokami M	Pretreatment prediction of the outcome of response-guided peginterferon- α and ribavirin therapy for chronic hepatitis C	J Gastro Hepatol	29(12)	1996-2005	2014

<u>Yoneda M</u>	Is the measurement of serum cytokeratin-18 useful for diagnosis or screening nonalcoholic steatohepatitis?	Hepatol Res	44(8)	827-8	2014
Nakade Y, <u>Yoneda M</u>	Prognostic factors for Regression from impaired glucose tolerance to Normal Glucose Regulation in Japanese patients with nonalcoholic fatty liver disease.	Intern Med	53(13)	1399-400	2014
Selitsky SR, Baran-Gale J, Honda M, Yamane D, Masaki T, Fannin EE, Guerra B, Shirasaki T, <u>Shimakami T</u> , Kaneko S, Lanford RE, Lemon SM, Sethupathy P.	Small tRNA-derived RNAs are increased and more abundant than microRNAs in chronic hepatitis B and C	Sci Rep	5	7625-	2015
Yamane D, McGivern DR, Wauthier E, Yi M, Madden VJ, Welsch C, Antes I, Wen Y, Chugh PE, McGee CE, Widman DG, Misumi I, Bandyopadhyay S, Kim S, <u>Shimakami T</u> , Oikawa T, Whitmire JK, Heise MT, Dittmer DP, Kao CC, Pitson SM, Merrill AH Jr, Reid LM, and Lemon SM.	Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation.	Nature Medicine	20	927-35	2014
Shirasaki T, Honda M, <u>Shimakami T</u> , Murai K, Shiimoto T, Okada H, Takabatake R, Tokumaru A, Sakai Y, Yamashita T, Lemon SM, Murakami S, Kaneko S.	Impaired IFN signaling in chronic hepatitis C patients with advanced fibrosis via the TGF- β signaling pathway	Hepatology	60	1519-30	2014
<u>Shimakami T</u> , Honda M, Shirasaki T, Takabatake R, Liu F, Murai K, Shiimoto T, Funaki M, Yamane D, Murakami S, Lemon SM, Kaneko S	The acyclic retinoid Peretinoin inhibits hepatitis C virus replication and infectious virus release in vitro	Sci Rep	4	4688-	2014

Li Y, Masaki T, <u>Shimakami T</u> , Lemon SM.	hnRNP L and NF90 Interact with Hepatitis C Virus 5'-Terminal Untranslated RNA and Promote Efficient Replication	J Virol	88	7199-209	2014
Matsuura K, <u>Watanabe T</u> , Iijima S, Murakami S, Fujiwara K, Orito E, Iio E, Endo M, Kusakabe A, Shinkai N, Miyaki T, Nojiri S, Joh T, Tanaka Y.	Serum interferon-gamma-inducibl e protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C.	Hepatol Res.	44(12)	1208-1216	2014
Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, <u>Watanabe T</u> , Tanaka Y.	Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.	Liver Int.	34(6)	890-5	2014
Matsuura K, Tanaka Y, <u>Watanabe T</u> , Fujiwara K, Orito E, Kurosaki M, Izumi N, Sakamoto N, Enomoto N, Yatsuhashi H, Kusakabe A, Shinkai N, Nojiri S, Joh T, Mizokami M.	ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.	J Viral Hepat.	21(7)	466-74	2014
<u>Watanabe T</u> , Hatakeyama H, Matsuda-Yasui C, Sato Y, Sudoh M, Takagi A, Hirata Y, Ohtsuki T, Arai M, Inoue K, Harashima H, Kohara M.	In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus.	SciRep.	4	4750	2014
<u>渡邊綱正</u> , 田中靖人.	C型肝炎治療効果に影響 するIL28B遺伝子多型と 肝内自然免疫応答の解析	Nagoya Medical Journal	54 (1)	45-50	2014

<u>Ishigami M</u> , Honda T, Ishizu Y, Onishi Y, Kamei H, Hayashi K, Ogura Y, Hirooka Y, Goto H.	Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients.	Liver Transpl	20	1221-1220	2014
Hayashi K, Katano Y, Ishizu Y, Kuzuya T, Honda T, <u>Ishigami M</u> , Itoh A, Hirooka Y, Ishikawa T, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H.	Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness.	<i>J Gastroenterol Hepatol</i>	30	173-183	2015
Tachi Y, Hirai T, Miyata A, Ohara K, Iida T, Ishizu Y, Honda T, Kuzuya T, Hayashi K, <u>Ishigami M</u> , Goto H.	Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response.	<i>Hepatol Res</i>	45	238-246	2015
Honda T, <u>Ishigami M</u> , Masuda H, Ishizu Y, Kuzuya T, Hayashi K, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Katano Y, Goto H.	Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.	<i>J Gastroenterol Hepatol</i>	30	321-328	2015
Tatsumi A, Maekawa S, Sato M, Komatsu N, Miura M, Amemiya F, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Enomoto N.	Liver Stiffness Measurement for Risk Assessment of Hepatocellular Carcinoma.	Hepatol Res	Article first published online : 20 OCT 2014, DOI: 10.1111/hepr.12377		

Miura M, Maekawa S, Sato M, Komatsu N, Tatsumi A, Takano S, Amemiya F, Nakayama Y, Inoue T, <u>Sakamoto M</u> , Enomoto N.	Deep sequencing analysis of variants resistant to the NS5A inhibitor daclatasvir in patients with genotype 1 in hepatitis C virus infection.	Hepatol Res	Article first published online : 10 APR 2014, DOI: 10.1111/hepr.12316		
Komatsu N, Motosugi U, Maekawa S, Shindo K, <u>Sakamoto M</u> , Sato M, Tatsumi A, Miura M, Amemiya F, Nakayama Y, Inoue T, Fukasawa M, Uetake T, Ohtaka M, Sato T, Asahina Y, Kurosaki M, Izumi N, Ichikawa T, Araki T, Enomoto N.	Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging.	Hepatol Res	44	1339-1346	2014
<u>坂本穰</u> 、榎本信幸	C型肝炎治療における宿主因子とウイルス因子	日本臨床	73 (2)	208-212	2015
<u>坂本穰</u> 、榎本信幸	DAA時代におけるインターフェロンの意義	Mebio	31	61-63	2014
<u>坂本穰</u> 、榎本信幸	線維化進展例に対する3剤併用療法	医学のあゆみ	249 (3)	237-241	2014
Umemura T, Ota M, Katsuyama Y, Wada S, Mori H, Maruyama A, Shibata S, Nozawa Y, Kimura T, Morita S, Joshita S, Komatsu M, Matsumoto A, Kamijo A, Kobayashi M, Takamatsu M, <u>Yoshizawa K</u> , Kiyosawa K, Tanaka E.	KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.	Hum Immunol	75	822-826	2014
Nozawa Y, Umemura T, Katsuyama Y, Shibata S, Kimura T, Morita S, Joshita S, Komatsu M, Matsumoto A, <u>Yoshizawa K</u> , Ota M, Tanaka E.	Genetic polymorphism in IFNL4 and response to pegylated interferon- α and ribavirin in Japanese chronic hepatitis C patients.	Tissue Antigens.	83	45-48	2014

Morita S, Matsumoto A, Umemura T, Shibata S, Kamijo N, Ichikawa Y, Kimura T, Joshita S, Komatsu M, <u>Yoshizawa K</u> , Tanaka E.	Characteristics and prediction of hepatitis B e-antigen negative hepatitis following seroconversion in patients with chronic hepatitis B.	Hepatol Res.	44	E45-53	2014
Okuhara S, Umemura T, Joshita S, Shibata S, Kimura T, Morita S, Komatsu M, Matsumoto A, <u>Yoshizawa K</u> , Katsuyama Y, Ota M, Tanaka E.	Serum Levels of Interleukin-22 and Hepatitis B Core-related Antigen Are Associated with Treatment Response to Entecavir Therapy in Chronic Hepatitis B.	Hepatol Res.	44	E172-180	2014
Sugawara K, Koushima Y, Inao M, Nakayama N, Nagoshi S, Yakabi K, Tamano M, Asabe S, Mishikawa K, Harada Y, Sekine C, Fukuya Y, Funtny J, Hashimoto Y, <u>Mochida S</u> .	Multicenter prospective study to optimize the efficacy of triple therapy with telaprevir in patients with genotype 1b HCV infection according to an algorithm based on the drug adherence, IL28B gene allele and viral response: the AG & RGT Trial.	Hepatol Res		2015 Jan 9. Doi: 10.1111/hrp r.12475 [Epub ahead of print].	2015
Fujii Y, Uchida Y, <u>Mochida-S</u>	Drug-induced immunologic hepatitis during combination therapy with dactasvir and asunaprevir.	Hepatology	61	400^401	2015
Uchida Y, Kouyama J-I, Naiki K, <u>Mochida-S</u> .	A novel simple assay system to quantify the percent HCV-RNA Levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors.	PloS One		9 (11): e112647. doi:10. 101371/ journal. pone. 0112647	2014
Oda K , Uto H, Kumagai K, Ido A, Kusumoto K, <u>Shimoda K</u> , Hayashi K, Stuver SO, Tanaka Y, Nishida N, Tokunaga K, Tsubouchi H	Impact of a single nucleotide polymorphism upstream of the IL28B gene in patients positive for anti-HCV antibody in an HCV hyperendemic area in Japan.	J Med Virol.86.1877-1885, 2014	85	1877-1885	2014

Ozono Y, Nagata K, Hasuike S, Iwakiri H, Yamada Y, Tsuchimochi M, Kusumoto K, Nakamura K, Sueta M, Abe H, Miike T, Tahara Y, Yamamoto S, Kato J, Ochiai T, Kuroki K, Kitanaka A, <u>Shimoda K</u>	Telaprevir triple therapy for patients with hepatitis C virus genotype 1 is effective and safe in the “real world”.	Hepato-gastroenterology			In press
Omata M, Nishiguchi S, <u>Ueno Y</u> , et al.	Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.	J Viral Hepat.	21	762-8	2014
Hirooka M, Koizumi Y, Miyake T, Ochi H, Tokumoto Y, Tada F, Matsuura B, Abe M, <u>Hiasa Y</u> .	Nonalcoholic fatty liver disease: portal hypertension due to outflow block in patients without cirrhosis.	Radiology.	274	597-604	2015
Kuroda T, Hirooka M, Koizumi M, Ochi H, Hisano Y, Bando K, Matsuura B, Kumagi T, <u>Hiasa Y</u> .	Pancreatic congestion in liver cirrhosis correlates with impaired insulin secretion.	J Gastroenterol		Oct 5 [Epub ahead of print]	2014
日浅陽一	肝臓疾患の最近のトピックス	診断と治療	102	1600-1605	2014
徳本良雄, 日浅陽一	新たな3剤併用療法 シメプレビル登場によって変わったこと	日本医事新報	4723	20-26	2014
Miyake T, Kumagi T, Furukawa S, Hirooka M, Kawasaki K, Koizumi M, Todo Y, Yamamoto S, Abe M, Kitai K, Matsuura B, <u>Hiasa Y</u> .	Hyperuricemia is a risk factor for the onset of impaired fasting glucose in men with a high plasma glucose level: a community-based study.	PLoS One	9	e107882	2014
徳本良雄, 日浅陽一.	C型肝硬変例における抗ウイルス治療戦略	Mebio	31	43-48	2014
Miyake T, Kumagi T, Furukawa S, Hirooka M, Kawasaki K, Koizumi M, Todo Y, Yamamoto S, Tokumoto Y, Ikeda Y, Abe M, Kitai K, Matsuura B, <u>Hiasa Y</u> .	Short sleep duration reduces the risk of nonalcoholic fatty liver disease onset in men: a community-based longitudinal cohort study.	J Gastroenterol		Aug 13 [Epub ahead of print]	2014

Watanabe T, Tokumoto Y, Hirooka M, Koizumi Y, Tada F, Ochi H, Abe M, Kumagi T, Ikeda Y, Matsuura B, Takada K, <u>Hiasa Y.</u>	An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion.	Intern Med	53	1343-1346	2014
Miyake T, Kumagi T, Hirooka M, Furukawa S, Kawasaki K, Koizumi M, Todo Y, Yamamoto S, Nunoi H, Tokumoto Y, Ikeda Y, Abe M, Kitai K, Matsuura B, <u>Hiasa Y.</u>	Significance of exercise in nonalcoholic fatty liver disease in men: a community-based large cross-sectional study.	J Gastroenterol	50	230-237	2015
<u>Genda T.</u> , Ichida T, Sakisaka S, Sata M, Tanaka E, Inui A, Egawa H, Umeshita K, Furukawa H, Kawasaki S, Inomata Y.	Waiting list mortality of patients with primary biliary cirrhosis in the Japanese transplant allocation system.	J Gastroenterol	49	324-331	2014
Narita Y, <u>Genda T.</u> , Tsuzura H, Sato S, Kanemitsu Y, Ishikawa S, Kikuchi T, Hirano K, Iijima K, Wada R, Ichida T.	Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy.	J Gastroenterol Hepatol.	29	137-143	2014
Tsuzura H, <u>Genda T.</u> , Sato S, Murata A, Kanemitsu Y, Narita Y, Ishikawa S, Kikuchi T, Mori M, Hirano K, Iijima K, Wada R, Ichida T.	Expression of aldo-keto reductase family 1 member B10 in the early stages of human hepatocarcinogenesis.	Int J Mol Sci.	15	6556-68	2014

効率的な肝炎ウイルス検査陽性者
フォローアップシステムの構築のための研究

平成26年度 総括・分担研究報告書

IV. 研究成果の刊行物

厚生労働科学研究費補助金 肝炎等克服政策研究事業

効率的な肝炎ウイルス検査陽性者フォローアップシステム
構築のための研究

(H26—肝政—一般—001)

平成 26 年度 総括・分担研究報告書

発行日 平成27(2015)年3月
発行者 「効率的な肝炎ウイルス検査陽性者フォローアップシステム
構築のための研究」
研究代表者 是永 匡紹
発行所 国立国際医療研究センター 肝炎・免疫研究センター
〒272-8516 千葉県市川市国府台1-7-1
TEL : 047-372-3501 FAX : 047-375-4766

